POMC-derived melanocortins inhibit food intake. In the adult rodent brain, POMC-expressing neurons are located in the arcuate nucleus (ARC) and the nucleus tractus solitarius (NTS), but it remains unclear how POMC neurons in these two brain nuclei regulate feeding behavior and metabolism differentially. Using pharmacogenetic methods to activate or deplete neuron groups in separate brain areas, in the present study, we show that POMC neurons in the ARC and NTS suppress feeding behavior at different time scales. Neurons were activated using the DREADD (designer receptors exclusively activated by designer drugs) method. The evolved human M3-muscarinic receptor was expressed in a selective population of POMC neurons by stereotaxic infusion of Cre-recombinase-dependent, adenoassociated virus vectors into the ARC or NTS of POMC-Cre mice. After injection of the human M3-muscarinic receptor ligand clozapine-N-oxide (1 mg/kg, i.p.), acute activation of NTS POMC neurons produced an immediate inhibition of feeding behavior. In contrast, chronic stimulation was required for ARC POMC neurons to suppress food intake. Using adeno-associated virus delivery of the diphtheria toxin receptor gene, we found that diphtheria toxin-induced ablation of POMC neurons in the ARC but not the NTS, increased food intake, reduced energy expenditure, and ultimately resulted in obesity and metabolic and endocrine disorders. Our results reveal different behavioral functions of POMC neurons in the ARC and NTS, suggesting that POMC neurons regulate feeding and energy homeostasis by integrating long-term adiposity signals from the hypothalamus and short-term satiety signals from the brainstem.
Introduction
POMC neurons play critical roles in maintaining normal feeding behavior and energy homeostasis (Schwartz et al., 2000; Morton et al., 2006) . Genetic and pharmacological studies have revealed that the activity of POMC neurons functions to reduce appetite, enhance metabolism, and increase energy expenditure. Ablating POMC neurons in the entire brain or mutating the POMC gene causes obesity in rodents and humans (Yaswen et al., 1999; Coll et al., 2004; Gropp et al., 2005; Xu et al., 2005) . Intraventricular administration of POMC-derived melanocortins such as ␣-melanocyte-stimulating hormone (␣-MSH) or its analogs suppresses food intake within hours (Fan et al., 1997) .
In the adult rodent brain, a majority of POMC neurons are located in the arcuate nucleus (ARC) of the hypothalamus (Cone, 2005; Padilla et al., 2012) . Moreover, melanocortin receptors are richly expressed in the downstream stations targeted by ARC POMC neurons (Cone, 2005) , suggesting that these neurons consist of a fundamental component in the neural circuit underlying feeding inhibition. However, optogenetic stimulation of POMC neurons in the ARC for 2 h does not inhibit food intake (Aponte et al., 2011) , implying that there are additional neuronal populations that mediate the acute inhibitory effect of melanocortin signaling. In addition to the ARC, the nucleus tractus solitarius (NTS) in the medulla also contains a substantial number of POMC-expressing neurons (Bronstein et al., 1992; Padilla et al., 2012) . The exact functional significance of these two different groups of POMC neurons has not been studied directly.
In this study, we examined the behavioral functions of POMC neurons by separately stimulating or ablating these two neuron populations. We used the DREADD (designer receptors exclusively activated by designer drugs) method for neuron activation (Armbruster et al., 2007; Alexander et al., 2009 ). The gene encoding the evolved human M3-muscarinic receptor (hM3Dq) was targeted selectively into POMC neurons in the ARC or NTS with a Cre-inducible adeno-associated virus (AAV) vector that carries a "double-floxed" inverted open reading frame (AAV DIO) (Ata-soy et al., 2008; Dong et al., 2010; Krashes et al., 2011) . Neurons were activated remotely by injection of the hM3Dq ligand clozapine-N-oxide (CNO). After discovering that feeding suppression required stimulation of these two neuron groups at different time scales, we went on to investigate the necessity of these neurons in maintaining energy homeostasis. A similar strategy of AAV vector design was used to express diphtheria toxin receptor (DTR) in POMC neurons in the ARC or NTS for later neuron lesion with the injection of DT (Buch et al., 2005; Gropp et al., 2005; Luquet et al., 2005) . Our results indicate that ablating POMC neurons in the ARC but not the NTS produces obesity and metabolic disorders. These findings highlight the functional heterogeneity among brain POMC neurons, suggesting that the ARC and NTS POMC neurons contribute to maintaining longterm energy homeostasis and controlling short-term food intake, respectively.
Materials and Methods
Mice. Animal care and use conformed to institutional guidelines of the National Institute of Biological Sciences (Beijing, China) and to governmental regulations. All experiments were performed on adult (8 -16 weeks of age) POMC-Cre mice of either sex expressing Cre recombinase under POMC promoter control [strain name Tg(Pomc1-cre)16Lowl/J, The Jackson Laboratory] . Cre recombinase in these mice has been shown to mediate recombination of floxed alleles efficiently in neurons within the ARC and NTS Huo et al., 2006) . In the ARC of these mice, Cre recombinase drives the expression of marker proteins that colocalize with POMC immunoreactivity. In the NTS, the distribution pattern of Cre-expressing neurons resembles that of neurons expressing POMC mRNA Huo et al., 2006) , but the precise identity of Cre-expressing neurons has not been tested with POMC immunohistochemistry. Mice were housed under controlled temperature (22-25°C) and 12 h light/dark cycles (light time, 9:30 P.M. to 9:30 A.M.) with standard chow diet (4% fat SPF Rodent Feed, Bejing Keao Xieli Feed Co.) and ad libitum drinking water.
AAV vectors for hM3Dq or DTR expression. We used Cre-inducible AAV vectors with an AAV DIO carrying the specific genes in the antisense orientation (Atasoy et al., 2008) . The coding sequence of hM3Dq-2A-mCherry, DTR, or mCherry was inserted into an AAV DIO vector with a CMV early enhancer/chicken ␤-actin (CAG) promoter (see Figs. 1 A, B, 4A). All coding sequences were in a 3Ј to 5Ј orientation relative to the promoter. The vectors were then sequenced and packaged in AAV serotype 2/9 vectors consisting of AAV2 ITR genomes pseudotyped with AAV9 serotype capsid proteins. AAV vectors were replicated in HEK293 cells with the triple plasmid transfection system purified by cesium chloride-density gradient centrifugation and desalination via dialysis against a physiological buffer (Duan et al., 2001) , resulting in AAV vector titers of Ͼ10 9 particles/l. Stereotaxic virus injection. Mice were injected with atropine (0.05 mg/ kg, i.p.) and anesthetized with pentobarbital (80 mg/kg, i.p.), placed in a temperature-controlled stereotaxic holder (BrainKing Biotech), and a small hole was opened in the skull. Pulled glass pipettes (ϳ20 m tip diameter) were filled with AAV and inserted into specific brain areas. For the ARC, AAV vectors (500 or 1000 nl) were infused with pressure (coordinate AP/DV/ML ϭ Ϫ1.7/Ϫ5.5/Ϯ0.2 mm; infusion speed ϭ 23 nl/ min; Nanoliter 2000 Injector, WPI). For the NTS, 500 nl of vector was injected into the medulla (coordinate ϭ Ϫ8.4/Ϫ3.3/0 mm). To activate neurons, AAV DIO hM3Dq-2A-mCherry vectors were injected into the ARC or NTS of POMC-Cre mice, which for simplicity are referred to as ARC hM3Dq mice and NTS hM3Dq mice, respectively. To ablate neurons, AAV DIO DTR vectors were injected into the ARC or NTS of POMC-Cre mice (referred to as ARC DTR mice and NTS DTR mice, respectively) and DT was injected 14 d later. To confirm lesion effects in the NTS, AAV DIO mCherry vectors were injected into the NTS of NTS DTR mice after behavioral studies. For control, AAV DIO mCherry virus was injected into the ARC or NTS of POMC-Cre mice (referred to as ARC mCherry mice and NTS mCherry mice, respectively). Mice were allowed to recover in individual cages for at least 2 weeks before the behavioral assays.
Measurement of food intake, meal pattern, body weight, and body mass composition. To measure food intake, each test cage was equipped with an individual food station that was placed on a digital scale (Zhenquan Technology). Food weight was recorded online through RS232 ports. ARC hM3Dq mice or NTS hM3Dq mice were first injected with saline during the first 2 d (1 l/g body weight, i.p.) at dark onset. They were then supplied with a single dose of CNO (1 mg/kg body weight in saline i.p.; 1 l/g) at dark onset during the next 2 d. On days 5 and 6, mice were given two injections of CNO, first at dark onset and then 5 h later. After the application of either saline or CNO, cumulative food intake at different time points (2, 5, 8, 10, 12 , and 24 h) were measured. The same procedures were performed in ARC mCherry mice and NTS mCherry mice to control the effect of CNO. The values of meal number and meal size were quantified using methods described previously (Zorrilla et al., 2005) . Briefly, food intake after dark onset was recorded every 5 min for 5 h. The minimal intermeal interval was 15 min and the criterion of minimal meal size was 50 mg. To examine the effects of chronic CNO application on ARC hM3Dq mice and NTS hM3Dq mice, animals received saline injections every 5 h during the first 2 d, then CNO injections every 5 h for 3 d.
To kill POMC neurons, ARC DTR mice and NTS DTR mice were given a single injection of DT (50 g/kg, i.p.). ARC mCherry mice and NTS mCherry mice were provided with the same dose of DT as a control. The body weights and food intakes of all DT-treated mice were monitored on a daily basis for 4 weeks. One month after DT injection, whole-body mass composition was examined with a benchtop nuclear magnetic resonance analyzer (Minispec Live Mouse Analyzer, Bruker).
Glucose tolerance tests and serum assays. One month after DT application, mice were fasted with free access to water 3 h before light onset. After 16 h of fasting, the end of the tail was cut horizontally with a razor blade and a small drop of blood was collected with gentle massaging for the measurement of baseline blood glucose level using a blood glucose meter (One Touch, Johnson & Johnson Medical). Mice were then given a 20% glucose solution (2 g/kg body weight, i.p.) and blood glucose levels were further sampled at the time points of 15, 30, 60, 90, and 120 min.
Lipid metabolism and corticosterone levels were measured ϳ40 d after DT injections. After overnight fasting, mice were anesthetized with isoflurane. Blood was drawn from the retrobulbar intraorbital capillary plexus and serum was then separated by centrifugation. Serum levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were analyzed by the Institute of Laboratory Animal Sciences at the Chinese Academy of Medical Sciences. The serum corticosterone levels were measured with a commercial corticosterone ELSA kit (catalog #ADI-900-097, Enzo Life Sciences).
Measurement of locomotor activity and oxygen consumption. The locomotor activity level of each mouse was quantified by measuring the total travel distance using a method described previously (Bjursell et al., 2008; Gong et al., 2011; Klockener et al., 2011) . Twenty days after DT treatment, mice were placed in a test cage (30 ϫ 30 cm) with an overhead infrared camera (KVS-5096S, Wanzhongxin Technology). Animal movement was videotaped at 5 fps and the horizontal locomotor activity was analyzed online with a custom-written MATLAB program. The travel distance of an individual mouse was clustered into different time periods in a day and then averaged across the test period of 6 d. Oxygen consumption was measured with an open-circuit calorimeter system (AccuScan Instruments). The measurement was taken every 2 min for 2 h during light cycles with room air as a reference and an air flow to the chambers of 0.5 l/min. Data were normalized to body weight.
Histology, immunostaining, and imaging. For c-Fos immunostaining, mice received an i.p. injection of either saline or CNO (1 mg/kg). Ninety minutes later, mice were anesthetized (300 mg/kg pentobarbital, i.p.) and perfused transcardially with cold saline and 4% paraformaldehyde in the PBS with 0.2% picric acid. Brains were extracted and postfixed in 4% paraformaldehyde overnight at 4°C and cryoprotected with 30% sucrose. Coronal sections (30 -40 m) were cut with a cryostat (CR 1900, Leica) and mounted on glass slides. Brain sections were reacted with rabbit anti-POMC antibody (1:400; lot #01181-3, Phoenix Pharmaceuticals) or rabbit anti-c-Fos antibody (1:200; produce #PC38, EMD Chemicals) overnight at 4°C and then incubated with Cy2-conjugated secondary antibody (1:500, lot #103581, Jackson ImmunoResearch) overnight at 4°C. Fluorescent images were acquired with a confocal microscope (DigitalEclipse A1, Nikon) and processed with Adobe Photoshop. Cell numbers were counted manually under an epifluorescence microscope.
Electrophysiological recordings. The method of electrophysiological recording from brain slices has been described in detail previously (Ren et al., 2011) . Briefly, adult mice were deeply anesthetized and decapitated. Brain sections were cut with a Vibratome (model #VT1000S, Leica) in ice-cold, oxygenated artificial CSF (aCSF) containing 125 mM NaCl, 2 mM CaCl 2 , 2.5 mM KCl, 1.3 mM MgCl 2 , 1.3 mM NaH 2 PO 4 , 1.3 mM Naascorbate, 0.6 mM Na-pyruvate, 25 mM NaHCO 3 , and 20 mM glucose, and then incubated in warm oxygenated aCSF (34°C) for 1 h. Brain slices were transferred into the recording chamber and superfused (2 ml/min) with oxygenated aCSF at room temperature (22-25°C). Whole-cell patch recordings or cell-attached patch recordings were performed with a computer-controlled amplifier (MultiClamp 700B, Molecular Devices). Whole-cell patch-clamp recording pipettes (4 -7 M⍀) were backfilled with internal solution containing the following: 130 mM K-gluconate, 10 mM HEPES, 0.6 mM EGTA, 5 mM KCl, 3 mM Na2ATP, 0.3 mM Na3GTP, 4 mM MgCl2, and 10 mM Na2phosphocreatine, pH 7.2-7.4. Series resistance (20 -30 M⍀) was compensated for in all whole-cell recordings. The pipettes for cell-attached recording (3-4 M⍀) contained bath solution and the seal resistance was ϳ200 M⍀. hM3Dq/mCherry ϩ POMC neurons were targeted in the ARC or NTS under the visual guidance of red fluorescent signals using an upright microscope (Examiner Z1, Zeiss). CNO dissolved in aCSF was released to the recording area with a small pressure using an 8-channel drug-delivery system (MPS-1, Inbio Life Science Instrument). Traces were low-pass filtered at 2.6 kHz and digitized at 10 kHz (DigiData 1440, Molecular Devices).
Statistical analysis. Data analysis was performed with MATLAB (MathWorks). The t test and ANOVA were used to determine the significance of differences between groups, and p Ͻ 0.05 was considered as significant. Group data are represented as means ϩ SEM in the figures.
Results

Selective activation of POMC neurons in the ARC or NTS
To activate POMC neurons selectively, AAV vectors were used to express the hM3Dq receptor, which has a high affinity for the pharmacologically inert ligand CNO but not endogenous neurotransmitters (Alexander et al., 2009) . The hM3Dq coding sequence was packaged into a Cre-recombinase-dependent AAV vector that enabled bicistronic expression of the red fluorescent protein mCherry (AAV DIO hM3Dq-2A-mCherry; Fig. 1A ). AAV DIO mCherry vectors were used as the control (Fig. 1B) . Two weeks after stereotaxic infusion of AAV DIO hM3Dq-2A-mCherry viral vectors into the ARC or the NTS of POMC-Cre mice, mCherry expression was detected exclusively in either of these two brain areas (Fig. 1C,D) . Red fluorescent mCherry signals were colocalized with POMC immunoreactivity in the majority (Ͼ95%) of the neurons in the ARC (Fig. 1E) . The efficiency of hM3Dq/mCherry expression was comparable among POMC neurons in the ARC and NTS. Using labeling of bicistronically expressed mCherry as a marker, clear hM3Dq expression was observed in ϳ70% of POMC-immunopositive neurons in the entire ARC of ARC hM3Dq mice (2050 Ϯ 254 hM3Dq/mCherry ϩ neurons of a total of ϳ3000 POMC ϩ neurons; mean Ϯ SEM; n ϭ 9 mice). Similarly, ϳ77% of POMC neurons in the NTS expressed hM3Dq (311 Ϯ 34 hM3Dq/mCherry ϩ cells of the reported total of ϳ400 POMC neurons; n ϭ 11 NTS hM3Dq mice) (Cone, 2005) .
To determine whether CNO could activate POMC neurons, targeted whole-cell recordings were made from hM3Dq/ mCherry ϩ POMC neurons in the ARC of brain slices. CNO administration (10 M) depolarized these cells significantly, from Ϫ57.1 Ϯ 2.0 mV to Ϫ45.7 Ϯ 2.4 mV ( p Ͻ 0.01; paired t test; n ϭ 5 cells) and increased the firing frequency of action potentials from 0.04 Ϯ 0.04 Hz to 1.30 Ϯ 0.30 Hz ( p Ͻ 0.05; paired t test; n ϭ 5 cells; Fig. 1F ). CNO, but not the aCSF control, remained capable of depolarizing ARC POMC neurons in the presence of the sodium channel blocker tetrodotoxin (1 M; **p Ͻ 0.01; t test between CNO and aCSF control; n ϭ 5 cells; Fig. 1G ), suggesting that CNO excited ARC POMC neurons directly without synaptic input. Similarly, cell-attached recordings demonstrated that CNO activated hM3Dq/mCherry ϩ POMC neurons effectively in the NTS (action potential firing frequency ϭ 1.5 Ϯ 0.9 Hz before CNO and 3.3 Ϯ 1.1 Hz during CNO; p Ͻ 0.05; paired t test; n ϭ 5 cells; Fig. 1H ).
The pattern of neuronal activation was then examined in vivo. CNO (1 mg/kg, i.p.) was injected into POMC-Cre mice with unilateral hM3Dq/mCherry expression in the ARC and c-Fos expression was used as an indicator of neuronal activity. The number of c-Fos ϩ cells (ϳ1000) in the ipsilateral ARC was approximately ninefold that in the contralateral side (Fig. 1I ) . In the NTS, the number of c-Fos ϩ neurons in NTS hM3Dq mice (ϳ300 cells) was similar, at ϳ9 times of that in NTS mCherry control mice (n ϭ 5 mice of either group; Fig. 1J ). In both the ARC and NTS, the overall distribution pattern of c-Fos ϩ cells resembled that of hM3Dq/mCherry ϩ POMC cells. By examining the dual-color fluorescent signals of a total of 7678 hM3Dq/mCherry ϩ neurons from the ARC of six ARC hM3Dq mice and 1392 cells from the NTS of five NTS hM3Dq mice, approximately half of hM3Dq/ mCherry ϩ neurons were found to be c-Fos positive in these two nuclei (53.9 Ϯ 2.6% in the ARC and 49.7 Ϯ 1.1% in the NTS; Fig.  1K ). However, in both areas, more than half of the c-Fos ϩ neurons lacked clear hM3Dq/mCherry expression (55.7 Ϯ 1.9% in the ARC and 56.4 Ϯ 3% in the NTS; Fig. 1L ), likely because CNO triggered c-Fos expression in nearby non-POMC neurons through synaptic connections from POMC neurons.
Acute feeding suppression by activating POMC neurons in the NTS but not the ARC After establishing the validity of pharmacogenetic activation of POMC neurons, the effect of CNO injection on food intake and body weight of ARC hM3Dq mice that expressed hM3Dq in the bilateral ARC was analyzed (Fig. 2 A, B ; n ϭ 9 mice). Saline injection into ARC hM3Dq mice was used as the self-control ( Fig. 2A ) and CNO injection into ARC mCherry mice was used as an additional control ( Fig. 2C; n ϭ 8 mice) . A two-way ANOVA was conducted to compare the effect of CNO injections and the du- ration after initial CNO injections. There was no significant effect on food intake after either a single CNO injection or 2 injections in 5 h intervals (ANOVA: drug effect F (2,96) ϭ 0.092, p ϭ 0.91 n ϭ 9 mice; Fig. 2A ). The duration was the only determining factor on food intake (F (3,96) ϭ 157.7, p Ͻ 0.001), and acute CNO administrations did not alter the body weight of ARC hM3Dq mice ( p ϭ 0.96 and 0.95; paired t test between saline and CNO and that between saline and CNO ϫ 2, respectively; n ϭ 9 mice; Fig. 2B ). Similar observations were made for ARC mCherry control mice (ANOVA: drug effect F (2,84) ϭ 0.38, p ϭ 0.69; n ϭ 8 mice; Fig.  2C ). However, the amount of daily food intake and body weight of ARC hM3Dq mice were significantly reduced after chronic activation of ARC POMC neurons with consecutive CNO injections for 3 d (5 h interval between injections; ANOVA on body weight of ARC hM3Dq mice: drug F (2,32) ϭ 5.5, p Ͻ 0.01; time F (2,32) ϭ 1.4, p ϭ 0.25; interaction between drug and time F (3,32) ϭ 5.23, p Ͻ 0.01; ANOVA on food intake of ARC hM3Dq mice: drug F (2,32) ϭ 3.5, p Ͻ 0.05; time F (2,32) ϭ 0.27, p ϭ 0.76; interaction between drug and time F (3,32) ϭ 2.16; p ϭ 0.11; n ϭ 5 mice; Fig. 2D ). As a control, chronic CNO injection did not change the food intake nor body weight of ARC mCherry mice significantly (ANOVA on bodyweight of ARC mCherry control mice: drug F (2,32) ϭ 0.07, p ϭ 0.93; time F (2,32) ϭ 0.10, p ϭ 0.91; interaction between drug and time F (3,32) ϭ 0.36; p ϭ 0.79; ANOVA on food intake of ARC mCherry control mice: drug F (2,32) ϭ 0.12, p ϭ 0.89; time F (2,32) ϭ 1.68, p ϭ 0.20; interaction between drug and time F (3,32) ϭ 0.52, p ϭ 0.67; n ϭ 5 mice). These observations suggest that long-term but not acute activation of ARC POMC neurons suppresses animal feeding behavior.
Interestingly, acute activation of NTS POMC neurons produced immediate inhibition of feeding behavior. Within the first 2 h of CNO injection, NTS hM3Dq mice exhibited an ϳ70% decrease in food intake (n ϭ 8 mice; Fig. 3A) . A significant inhibitory effect on the amount of accumulative food consumption lasted for up to 5 h (ANOVA: drug F (2,84) ϭ 5.05, p Ͻ 0.01; time F (3,84) ϭ 97.52, p Ͻ 0.001; Bonferroni post hoc tests after ANOVA: **p Ͻ 0.01; ***p Ͻ 0.001; n ϭ 8 mice; Fig. 3A ). Meal number and meal size were also reduced (*p ϭ 0.034; ***p Ͻ 0.001; paired t test; n ϭ 8 mice; Fig. 3 B, C) . The effective duration of CNO is consistent with an earlier study on the effective duration of in vivo CNO application (Alexander et al., 2009) . CNO injections into NTS mCherry mice given as a control did not affect food intake (ANOVA: drug F (2,60) ϭ 3.1, p ϭ 0.06; time F (3,60) ϭ 260.8, p Ͻ 0.001; interaction between drug and time F (6,60) ϭ 1.2, p ϭ 0.35; n ϭ 6 mice; Fig. 3D ). A second CNO injection 5 h after the initial injection prolonged the inhibition for at least an additional 3 h (***p Ͻ 0.001; post hoc tests after ANOVA; n ϭ 8 mice; Fig. 3A ), but NTS hM3Dq mice compensated for the inhibited food intake during the next few hours (ANOVA: interaction between drug and time F (12,147) ϭ 4.13, p Ͻ 0.001; Bonferroni post hoc tests after ANOVA: **p Ͻ 0.01; ***p Ͻ 0.001; n ϭ 8 mice; Fig. 3E ). This led to an apparently normal amount of cumulative food intake on a daily basis and normal body weights for NTS hM3Dq mice ( p ϭ 0.84 and 0.81 for paired t test between saline and CNO and that between saline and CNO ϫ 2, respectively; n ϭ 8 mice; Fig.  3 A, F ) . Locomotor activity was measured to determine whether the suppression of food intake was associated with a reduction in activity or arousal levels. CNO injections did not change the locomotor activity of NTS hM3Dq mice (2-way ANOVA: drug F (2,75) ϭ 0.22, p ϭ 0.80; time F (4,75) ϭ 73.4, p Ͻ 0.001; interaction between drug and time F (8, 75) ϭ 0.1; p ϭ 0.99; n ϭ 6 mice; Fig.  3G ), suggesting that acute activation of NTS POMC neurons did not change motor ability nor arousal levels.
When NTS hM3Dq mice were given chronic stimulation with multiple CNO injections for 3 d, daily food intakes and body weights were decreased significantly for the first day but then rebounded during the following days (ANOVA on food intake: drug F (2,32) ϭ 11.15, p Ͻ 0.001; time F (2,32) ϭ 5.75; p Ͻ 0.01; interaction between drug and time F (3,32) ϭ 2.87; p ϭ 0.05; ANOVA on bodyweight: drug F (2,32) ϭ 15.0, p Ͻ 0.001; time F (2,32) ϭ 0.59, p ϭ 0.56; interaction between drug and time F (3,32) ϭ 0.68; p ϭ 0.57; n ϭ 5 mice; Fig. 3H ). In contrast, the food intakes and body weights of NTS mCherry control mice were not affected by chronic CNO application (ANOVA on food intake: drug F (2,32) ϭ 0.41; p ϭ 0.67; time F (2,32) ϭ 1.79; p ϭ 0.18; interaction between drug and time F (3,32) ϭ 0.71; p ϭ 0.55; ANOVA on body weight: drug F (2,32) ϭ 0.76, p ϭ 0.48; time F (2,32) ϭ 0.30, p ϭ 0.75; interaction between drug and time F (3,32) ϭ 0.25, p ϭ 0.86; n ϭ 5 mice). The data from NTS hM3Dq mice thus indicate that the activity of NTS POMC neurons is responsible for acute but not chronic inhibition of feeding behavior.
Selective ablation of POMC neurons in the ARC but not the NTS causes obesity
The necessity of ARC or NTS POMC neurons in regulating energy homeostasis was investigated by ablating these two neuron populations separately. AAV DIO DTR viral vectors were infused into the ARC or the NTS of POMC-Cre mice (ARC DTR and NTS DTR mice, respectively) to express DTR in POMC neurons (Fig. 4A) . Figure 4B , left, shows the representative effect of killing ARC POMC neurons after an injection of DT (50 g/kg, i.p.) into an ARC DTR mouse. By counting the number of neurons with POMC immunoreactivity in the ARC, DT injection was found to kill 60 -100% of POMC neurons in the ARC (n ϭ 22 mice). Due to the difficulty in labeling NTS POMC neurons with immunostaining methods (Bronstein et al., 1992; Huo et al., 2006) , AAV DIO mCherry vectors was delivered to label POMC neurons in the NTS after behavioral tests. DT reduced the number of mCherry ϩ neurons drastically in the NTS of NTS DTR mice (Fig. 4B, right) , whereas it did not induce any apparent change in the distribution pattern of mCherry ϩ neurons in NTS mCherry control mice (data not shown). Therefore, POMC neurons in either the ARC or NTS could be separately ablated by taking the approach of expressing DTR with Credependent AAV vectors.
Ablation of POMC neurons in the ARC resulted in obesity in a substantial number of ARC DTR mice (Fig. 4C) . The extent of body weight gain was negatively correlated with the number of surviving POMC neurons (Pearson's correlation coefficient r ϭ Ϫ0.81; p Ͻ 0.001), and it appears that ϳ500 cells in the ARC were sufficient to maintain normal body weight (Fig. 4D) . The ARC DTR mice with Ͻ500 POMC neurons in the ARC consumed significantly more food than the ARC mCherry control mice (ANOVA: lesion F (3,675) ϭ 40.14, p Ͻ 0.001; time F (26,675) ϭ 1.523, p ϭ 0.056; interaction between lesion and time F (78,675) ϭ 3.148, p Ͻ 0.001; Bonferroni post hoc tests after two-way ANOVA: p Ͻ 0.01 for day 1 and p Ͻ 0.001 thereafter between ARC DTR and ARC mCherry mice; Fig. 4E ). Lesions of ARC POMC neurons also resulted in a steady increase in body weight (ANOVA: lesion F (3,1377) ϭ 35.23, p Ͻ 0.001; time F (26,1377) ϭ 26.91, p Ͻ 0.001; interaction between lesion and time F (78,1377) ϭ 25.93, p Ͻ 0.001. Bonferroni post hoc tests after two-way ANOVA: p Ͻ 0.01 for days 6 and 7 and p Ͻ 0.001 after day 7 between ARC DTR and ARC mCherry mice; Fig. 4F ). In addition to increased food intake, energy expenditure was reduced in the obese ARC DTR mice. Their locomotor activity was significantly lower than that of ARC mCherry control mice during the dark phase of the light cycles (ANOVA: lesion F (1,28) ϭ 130, p Ͻ 0.001; dark/light phase F (1,28) ϭ 37.3, p Ͻ 0.001; interaction between lesion and dark/light phase F (1,28) ϭ 20.8, p Ͻ 0.001; Bonferroni post hoc tests after two-way ANOVA: p Ͻ 0.001 for tests between ARC DTR and ARC mCherry mice for dark phase; p Ͼ 0.05 for light phase; n ϭ 8 mice for each group; Fig. 5A ). Consistently, the oxygen metabolism of DT-treated ARC DTR mice was lower than that of ARC mCherry control mice (***p Ͻ 0.001; between-group t test, Fig. 5B) .
The ARC DTR mice had markedly higher body fat mass and lower lean mass (***p Ͻ 0.001; t test between ARC DTR and ARC mCherry mice; Fig. 6A ) and exhibited a broad spectrum of metabolic and endocrine disorders associated with obesity. ARC DTR mice had significantly higher levels of total serum cholesterol, highdensity lipoprotein cholesterol, and low-density lipoprotein cholesterol serum lipids (*p Ͻ 0.05; t tests between ARC mCherry and ARC DTR mice injected with DT) but not triglycerides (p ϭ 0.41; t test; Fig. 6B ). These mice showed fasting hyperglycemia and impaired glucose tolerance (ANOVA: lesion F (3, 132) (Fig. 4E ), body weight (Fig. 4F) , body composition, lipid and glucose metabolism, or corticosterone levels (Fig. 6) . Therefore, POMC neurons in the ARC but not in the NTS are necessary for maintaining normal food intake, metabolism, and body weight.
Discussion
In this study, we examined the behavioral functions of POMC neurons in the ARC and NTS by selectively manipulating these two neuronal populations with pharmacogenetic approaches. Chronic but not acute activation of ARC POMC neurons reduced food intake. Moreover, ablating these neurons resulted in hyperphasia, obesity, and metabolism disorders. In contrast, acute stimulation of NTS POMC neurons rapidly suppressed feeding, but killing these neurons did not produce any obvious changes in feeding behavior or body weight. These results indicate that POMC neurons in the ARC and NTS play different roles in regulating feeding behavior and metabolism. Specifically, our observations are consistent with the model suggesting that the activity of ARC POMC neurons is critical for maintaining long-term energy homeostasis, but that of NTS POMC neurons contributes to short-term feeding control in response to satiety signals.
Previous genetic and pharmacological studies have established the important functions of POMC signals in the regulation of feeding behavior and energy homeostasis (Yaswen et al., 1999; McMinn et al., 2000; Challis et al., 2004) . However, it has been challenging to determine the functions of separate populations of POMC neurons in the ARC and NTS of adult animals. POMC is expressed dynamically in numerous brain areas in the developing mouse brain (Padilla et al., 2010; Padilla et al., 2012) . Therefore, knocking out the POMC gene may alter neural circuits that are not directly related to feeding regulation in the adult brain. Similarly, many non-POMC neurons in the adult may be ablated by taking the traditional approach of crossing POMCCre mouse with the iDTR mouse line. The pharmacogenetic approaches in the present study have several advantages that overcome the technical limits of prior studies. Stereotaxic viral gene delivery into the adult brain avoided the potential off-target effect in transgenic animals that drives gene expression from the time of gestation (Padilla et al., 2012) . More importantly, separate manipulations allowed us to probe the behavioral functions of POMC neurons selectively in the ARC and NTS. Finally, activation and lesion facilitated the study of the sufficiency and necessity of adult POMC neurons in behavioral regulation. Our results confirm and extend our understanding about the behavioral functions of the central melanocortin system. Consistent with recent optogenetic stimulation of ARC POMC neurons (Aponte et al., 2011) , we have shown that feeding suppression was produced only by long-term (over a day) but not acute stimulation (several hours) of these neurons. In addition, we have found that selective lesions of POMC neurons in the ARC but not the NTS resulted in obesity, lower energy expenditure, and numerous metabolic and endocrine disorders that are typically associated with obesity. The behavioral effects of ablating POMC neurons in the ARC alone resembled the obesity phenotype produced by removing POMC neurons in the entire brain (Gropp et al., 2005) , indicating that ARC but not NTS POMC neurons are critical for maintaining normal body weight. Selective expression of the leptin receptor in brain POMC neurons increases the activity level of the db/db mice that lack functional leptin receptors (Huo et al., 2009) . Consistently, we found that ablating POMC neurons in the ARC reduced animal locomotor activity and oxygen consumption, suggesting that these neurons control energy homeostasis by both reducing food intake and increasing energy expenditure. ARC POMC neurons are activated by leptin and glucose (Cowley et al., 2001; Ibrahim et al., 2003; Parton et al., 2007) . These neurons may modulate feedingand activity-related neural circuits by responding to slow metabolic cues in the hypothalamus.
Another key finding of this study is that acute activation of NTS POMC neurons leads to immediate suppression of food intake. Many neurons in the NTS of the medulla express POMC mRNA and are believed to synthesize POMC peptides (Bronstein et al., 1992) . By delivering Cre-dependent AAV vectors, we found that POMC-Cre mice can be used to express the CNO receptor hM3Dq selectively in the putative POMC neurons in the NTS. Acute stimulation of NTS but not ARC POMC neurons was capable of suppressing feeding behavior, suggesting that the rapid inhibitory effect of melanocortins might be mediated by the neural circuits downstream of NTS POMC neurons (Fan et al., 1997) . Electrical stimulation of vagal afferent fibers has been found to induce EPSCs directly in NTS POMC neurons (Appleyard et al., 2005) . In addition, gastric distention and i.p. injection of the satiety signal cholecystokinin activates NTS neurons, a substantial number of which are believed to be POMC-ergic (Rinaman et al., 1998; Fan et al., 2004; Appleyard et al., 2005) . Therefore, NTS POMC neurons may sense short-term satiety signals from visceral afferents to inhibit feeding behavior rapidly.
What might be the circuit mechanisms underlying the functional disparity between POMC neurons in the ARC and the NTS? The axonal terminals of ARC POMC neurons mainly terminate in the forebrain, including the paraventricular nucleus, dorsomedial hypothalamus, lateral hypothalamus, and central amygdala (Schwartz et al., 2000; Cone, 2005) . These areas also receive strong input from ARC agouti-related protein neurons, which stimulate appetite and decrease metabolism powerfully (Aponte et al., 2011; Krashes et al., 2011) . By interacting with agouti-related protein neurons, POMC neurons in the ARC may influence their downstream stations in the forebrain to adjust the set point of body weight and energy homeostasis. Conversely, NTS POMC neurons mainly project to the caudal medulla and spinal cord (Tsou et al., 1986; Palkovits et al., 1987; Zheng et al., 2005) , where neural circuits may be more directly involved in executing satiety-trigged feeding suppression. In addition to distinct axonal projection targets, POMC neurons in the ARC and NTS differ in numbers. There are ϳ3000 POMC neurons in the ARC, whereas only ϳ400 POMC neurons are present in the NTS (Hentges et al., 2004; Cone, 2005) . Ablation of NTS POMC neurons lacks an obvious behavioral effect, possibly because of functional compensation by long-term activity of POMC neurons in the ARC and changes in other components of the feeding circuit (Pinto et al., 2004) .
Our present results may also have clinical implications. Although loss-of-function mutations of the POMC genes are associated with early-onset obesity in humans (Krude et al., 1998) , obesity can also be produced by mutations of melanocortin receptors or disorders that are indirectly related to the central melanocortin signaling (Farooqi et al., 2003) . Nasal application of ␣-MSH lacks consistent effects on treating human obesity (Hallschmid et al., 2004) , raising questions about the validity of melanocortin-based therapeutics. Our present results show that chronic stimulation of POMC neurons can suppress daily food intake effectively and reduce body weight mildly. However, obesity can only be induced after Ͼ80% of POMC neurons in the ARC are ablated, suggesting a large degree of redundancy in melanocortin signaling. Anti-obesity therapeutics based on melanocortins may require a personalized medical approach. Nasal application of ␣-MSH may be rendered more effective by targeting obese persons with severe POMC deficiency.
